SPI Pharma

spipharma.com

For over 75 years, we have supplied the pharmaceutical industry with highly engineered products and innovative solutions that improve the formulation and delivery of drug products to meet patient needs. Our functional excipients and active ingredients meet the highest-quality standards possible and can offer customized, cost-effective options for many applications.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MERCK TO SPIN OFF WOMEN’S HEALTH AND BIOSIMILAR DRUG BUSINESSES

The Globe and Mail | February 05, 2020

news image

Merck & Co Inc said on Wednesday it will spin off its women’s health, biosimilar drugs and older products into a separate publicly traded company as it tightens its focus on growth drivers like cancer drug Keytruda and vaccines. The new company’s assets currently make up around 15 per cent of Merck’s total sales and around half of its drugs that treat people. Merck will retain its animal health business, as well as drugs used for acute care in hospitals such as Bridion, whi...

Read More

BUSINESS INSIGHTS

KYOWA KIRIN EXPANDS LICENSE AGREEMENT WITH SYNAFFIX AND TAKES EXCLUSIVE TARGET RIGHTS BASED ON LATEST POSITIVE ADC DATA

Synaffix | July 01, 2022

news image

Synaffix B.V. a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates with best-in-class therapeutic index, today announces that Kyowa Kirin Co., Ltd.a global specialty pharmaceutical company that strives to create new value through the pursuit of advances in life sciences and technologies, has expanded the license agreement with Synaffix by adding a third ADC target to its research evaluation and development effor...

Read More

BUSINESS INSIGHTS

SIMULATIONS PLUS COLLABORATES WITH MULTINATIONAL PHARMACEUTICAL COMPANY TO PROVIDE MODELING & SIMULATION SUPPORT FOR COVID-19 TREATMENT

Simulations Plus, Inc | June 24, 2022

news image

Simulations Plus, Inc. a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that its Cognigen division worked with a major pharmaceutical company to implement modeling and simulation activities to support the development of a candidate COVID-19 therapy. This modeling and simulation work provided significant contributions towards regulatory submissions for the compound. Early in the COVID-19 pandemic, the pharma...

Read More

JUDGE WIPES OUT BIOGEN'S TECFIDERA PATENT PROTECTIONS IN SUIT AGAINST MYLAN

Fiercepharma | June 18, 2020

news image

In the high-stakes patent fight between Biogen and Mylan over Tecfidera’s main remaining patent, Mylan has scored a major win in federal court. U.S. District Judge Irene Keeley said Mylan “demonstrated by clear and convincing evidence” that certain claims of Biogen’s '514 patent are invalid for “lack of written description.” The decision threatens Biogen’s bestselling medicine with early generics; Tecfidera, a multiple sclerosis drug, generated $3.3 ...

Read More
news image

MERCK TO SPIN OFF WOMEN’S HEALTH AND BIOSIMILAR DRUG BUSINESSES

The Globe and Mail | February 05, 2020

Merck & Co Inc said on Wednesday it will spin off its women’s health, biosimilar drugs and older products into a separate publicly traded company as it tightens its focus on growth drivers like cancer drug Keytruda and vaccines. The new company’s assets currently make up around 15 per cent of Merck’s total sales and around half of its drugs that treat people. Merck will retain its animal health business, as well as drugs used for acute care in hospitals such as Bridion, whi...

Read More
news image

BUSINESS INSIGHTS

KYOWA KIRIN EXPANDS LICENSE AGREEMENT WITH SYNAFFIX AND TAKES EXCLUSIVE TARGET RIGHTS BASED ON LATEST POSITIVE ADC DATA

Synaffix | July 01, 2022

Synaffix B.V. a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates with best-in-class therapeutic index, today announces that Kyowa Kirin Co., Ltd.a global specialty pharmaceutical company that strives to create new value through the pursuit of advances in life sciences and technologies, has expanded the license agreement with Synaffix by adding a third ADC target to its research evaluation and development effor...

Read More
news image

BUSINESS INSIGHTS

SIMULATIONS PLUS COLLABORATES WITH MULTINATIONAL PHARMACEUTICAL COMPANY TO PROVIDE MODELING & SIMULATION SUPPORT FOR COVID-19 TREATMENT

Simulations Plus, Inc | June 24, 2022

Simulations Plus, Inc. a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that its Cognigen division worked with a major pharmaceutical company to implement modeling and simulation activities to support the development of a candidate COVID-19 therapy. This modeling and simulation work provided significant contributions towards regulatory submissions for the compound. Early in the COVID-19 pandemic, the pharma...

Read More
news image

JUDGE WIPES OUT BIOGEN'S TECFIDERA PATENT PROTECTIONS IN SUIT AGAINST MYLAN

Fiercepharma | June 18, 2020

In the high-stakes patent fight between Biogen and Mylan over Tecfidera’s main remaining patent, Mylan has scored a major win in federal court. U.S. District Judge Irene Keeley said Mylan “demonstrated by clear and convincing evidence” that certain claims of Biogen’s '514 patent are invalid for “lack of written description.” The decision threatens Biogen’s bestselling medicine with early generics; Tecfidera, a multiple sclerosis drug, generated $3.3 ...

Read More